- Country: Norway
- Summary: Monitoring of the Drugs Adalimumab, Infliximab and Rituximab; Serum Concentration and Antibody Tests for Bergen Hospital Trust
- NOT Ref No: 91348126
- Deadline: 24 Nov 2023
- Financier: Self Financed
- Purchaser Ownership: Government
- Tender Value: NOK 6750000.00
- Notice Type: Tender
- Document Ref. No.: 658515-2023
- Purchaser's Detail:Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.
- Description:
- Framework agreement for the purchase of tests for measuring the concentrations of and antibodies directed against the drugs Adalimumab, Infliximab and Rituximab in human serum.
Doc Title: Laboratory reagents
Contract Type: Supplies - Documents:
If you are registered member, kindly login to view full details of this tender notice:
CLICK HERE TO LOGINMonitoring of the Drugs Adalimumab, Infliximab and Rituximab; Serum Concentration and Antibody Tests for Bergen Hospital Trust - Norway Tender
The SYKEHUSINNKJØP HF, a Government sector organization in Norway, has announced a new tender for Monitoring of the Drugs Adalimumab, Infliximab and Rituximab; Serum Concentration and Antibody Tests for Bergen Hospital Trust. This tender is published on NorwayTenders under NOT Ref No: 91348126 and is categorized as a Tender. Interested and eligible suppliers are invited to participate by reviewing the tender documents and submitting their bids before the deadline on 2023-11-24.
The estimated tender value is NOK 6750000.00, and full details, including technical specifications and submission requirements, are provided in the official tender documents. Ensure all submissions meet the criteria outlined to be considered for evaluation.
